{"protocolSection":{"identificationModule":{"nctId":"NCT06134622","orgStudyIdInfo":{"id":"ASSET-IT"},"organization":{"fullName":"The First Affiliated Hospital of University of Science and Technology of China","class":"OTHER"},"briefTitle":"Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)","officialTitle":"Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)","acronym":"ASSET-IT"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-01-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-12","studyFirstSubmitQcDate":"2023-11-15","studyFirstPostDateStruct":{"date":"2023-11-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-15","lastUpdatePostDateStruct":{"date":"2023-11-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Wei Hu","investigatorTitle":"professor","investigatorAffiliation":"The First Affiliated Hospital of University of Science and Technology of China"},"leadSponsor":{"name":"The First Affiliated Hospital of University of Science and Technology of China","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis for patients with AIS.","detailedDescription":"The standard treatment for acute ischemic stroke is intravenous thrombolysis to dissolve fibrin and restore blood flow. However, reocclusion of blood vessels and stroke progression remain challenges after this treatment."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["tirofiban","intravenous thrombolysis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"randomized, double-blind trial","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":832,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intravenous thrombolysis plus tirofiban administration","type":"EXPERIMENTAL","description":"Patients will receive Intravenous thrombolysis and tirofiban administration","interventionNames":["Drug: Intravenous thrombolysis plus tirofiban"]},{"label":"Intravenous thrombolysis plus placebo administration","type":"ACTIVE_COMPARATOR","description":"Patients will receive Intravenous thrombolysis and placebo (saline) administration","interventionNames":["Drug: Intravenous thrombolysis plus placebo"]}],"interventions":[{"type":"DRUG","name":"Intravenous thrombolysis plus tirofiban","description":"Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.","armGroupLabels":["Intravenous thrombolysis plus tirofiban administration"]},{"type":"DRUG","name":"Intravenous thrombolysis plus placebo","description":"placebo (saline)","armGroupLabels":["Intravenous thrombolysis plus placebo administration"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"a modified Rankin Score of 0-1","description":"modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)","timeFrame":"90 (± 14 days) after procedure"}],"secondaryOutcomes":[{"measure":"a modified Rankin Score of 0-3","description":"modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)","timeFrame":"90 (± 14 days) after procedure"},{"measure":"Modified Rankin Score","description":"modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)","timeFrame":"90 (± 14 days) after procedure"},{"measure":"NIHSS score","description":"The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit.","timeFrame":"24 hours after procedure"},{"measure":"mortality","description":"(Number of subjects who died at 90-day follow-up/total number of subjects who participated in 90-day follow-up) x100%","timeFrame":"90 (± 14 days) after procedure"},{"measure":"symptomatic intracerebral hemorrhage (ICH)","description":"SICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death.","timeFrame":"within 72 hours after procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Onset of ischemic stroke symptoms ≤4;5 hours, treated with intravenous alteplase or tenecteplase according to guidelines;\n2. NIHSS score before intravenous thrombolysis ≤25;\n3. Age ≥18 and ≤80 years;\n4. Patient or legal representative signs an informed consent form.\n\nExclusion Criteria:\n\n1. Presence of contraindications for intravenous thrombolysis;\n2. Pre-stroke mRS score \\>1;\n3. Patients undergoing mechanical thrombectomy or other intravascular treatments (e;g;, intra-arterial thrombolysis);\n4. Known history of atrial fibrillation or emergency electrocardiogram indicating atrial fibrillation;\n5. Pregnant or lactating women;\n6. NCCT, CTA source images, or MRI-DWI showing ASPECTS or PC-ASPECTS \\<6;\n7. Currently participating in other clinical trials;\n8. Known genetic or acquired bleeding diathesis, lack of anticoagulant factors, or oral anticoagulant drugs and INR \\> 1.7; or treated with direct oral anticoagulant agents in the prior 48 hours;\n9. Severe renal failure, defined as serum creatinine \\>3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate \\[GFR\\] \\<30, or patients requiring hemodialysis or peritoneal dialysis;\n10. Liver dysfunction (ALT \\>2 times the upper limit of normal or AST \\>2 times the upper limit of normal);\n11. Known allergy to tirofiban or other IIb/IIIa inhibitors;\n12. Expected lifespan \\<1 year;\n13. Patients unable to complete the 90-day follow-up (e.g., no fixed residence, overseas patients).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Wei Hu, MD, PhD","role":"CONTACT","phone":"+86 055162284313","email":"andinghu@ustc.edu.cn"}],"locations":[{"facility":"The First Affiliated Hospital of University of Science and Technology of China","city":"Hefei","state":"Anhui","zip":"230001","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Acute Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077466","term":"Tirofiban"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"browseLeaves":[{"id":"M1807","name":"Tirofiban","asFound":"Abacavir","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}